Neoadjuvant immune checkpoint inhibitor (ICI) therapy may enable patients with high-risk hepatocellular carcinoma (HCC) to achieve outcomes similar to those undergoing upfront surgery. Administering ...
A partnership between Mount Sinai and local Ugandan physicians to pioneer MWA at the Kyabirwa Surgical Center highlights the ...
Neoadjuvant immunotherapy in high-risk patients with hepatocellular carcinoma (HCC) led to similar recurrence-free survival (RFS) and margin-negative resection rates compared with patients undergoing ...
Outcomes for advanced hepatocellular carcinoma with pulmonary metastasis: Surgical vs. immunotherapy
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, with over 70% of patients diagnosed at an advanced stage due to the absence of symptoms. A key characteristic of ...
Surgical resection and local ablative therapies are also limited by high recurrence rates, highlighting a need for adjuvant and/or neoadjuvant therapies. A majority of patients with HCC are diagnosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback